Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the weight loss drugs, according to a new report.

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially benefiting millions of Americans struggling with obesity.

The Trump administration is reportedly considering a way to ease Medicare and Medicaid into covering GLP-1 drugs like Ozempic and Mounjaro for obesity starting as soon as next year. Why it matters: The Health and Human Services Department in April rejected a Biden administration proposal to allow Medicare and Medicaid to cover the injections for weight-loss.